Drugs News and Research

RSS

Strategy for harnessing physics for health

Following a workshop hosted by the CERN European particle physics laboratory in February, doctors and physicists today published a strategy for harnessing physics for health. Techniques developed for physics research have a long history of application in medicine. Today's news recognises that synergy, and sets out a programme of strengthened collaboration.

4 Jun 2010

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Biologists at the California Institute of Technology have pinpointed molecular changes that helped allow the global spread of resistance to the antiviral medication Tamiflu (oseltamivir) among strains of the seasonal H1N1 flu virus.

4 Jun 2010

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

A team of investigators at Rational Therapeutics, Inc. and the Malcolm Todd Cancer Institute (Long Beach, Calif.) has reported that functional profiling using ex-vivo analysis of programmed cell death (EVA/PCD) can be used to prescribe treatment regimens that double the response rate and survival in patients with Stage IV non-small cell lung cancer (NSCLC). The findings of their phase II clinical trial will be presented on Sunday, June 6th at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

4 Jun 2010

Study: Rash adolescent behaviors tied to biological motivations

There are biological motivations behind the stereotypically poor decisions and risky behavior associated with adolescence, new research from a University of Texas at Austin psychologist reveals.

4 Jun 2010

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

The John Theurer Cancer Center at Hackensack University Medical Center announced today that its physicians and researchers will present 16 abstracts on treatment and diagnostic progress in many different areas of oncology during the Annual Meeting of American Society of Clinical Oncology in Chicago, IL from June 4-8.

4 Jun 2010

Multiple sclerosis risk sharing scheme: A costly failure

The multiple sclerosis risk sharing scheme is "a costly failure" and should not be continued, according to researchers on bmj.com today. They argue that the biggest losers are the other NHS patients who would otherwise have benefited from the money spent on the scheme, estimated to be around -50m per year since it was set up in 2002.

4 Jun 2010

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Nymox Pharmaceutical Corporation is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. The symposium was held between 6:00 and 7:00 pm EDT on Tuesday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia and featured expert panel discussions on the new therapy.

4 Jun 2010

Chemotherapy-induced amenorrhea improves survival in premenopausal women with early stage breast cancer

Chemotherapy-induced amenorrhea in premenopausal women being treated for early stage breast cancer was associated with significantly improved patient survival, according to a study published this week in the New England Journal of Medicine by the National Surgical Adjuvant Breast and Bowel Project (NSABP) in collaboration with leading US cancer centers and cooperative cancer research groups.

4 Jun 2010

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

The liver scarring of α1-antitrypsin deficiency, the most common genetic cause for which children undergo liver transplantation, might be reversed or prevented with a medication that has long been used to treat seizures, according to findings from Children's Hospital of Pittsburgh of UPMC and the University of Pittsburgh School of Medicine that will published in Science and are available online today through the Science Express website.

4 Jun 2010

20% of returning war veterans report PTSD or major depression

This past Memorial Day honored those Americans who have died in military service including over 4,000 in Iraq and 1,000 fallen soldiers in Afghanistan. According to the latest Pentagon study, released in April this year, nearly 20 percent—or one in five returning war veterans—reported symptoms of post-traumatic stress disorder (PTSD) or major depression. The study also reports that approximately half of them sought treatment.

4 Jun 2010

Key regulator of fat cell differentiation identified

New research led by UCD Conway Fellow, Professor Johan Ericsson has identified a key regulator of fat cell differentiation that may be a novel target for obesity drugs. The results of the research are published in the current edition of the scientific journal, Proceedings of the National Academy of Sciences (PNAS).

4 Jun 2010

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced its unaudited financial results for the fourth fiscal quarter and the full fiscal year ended March 31, 2010.

4 Jun 2010

Research finding suggests possibilities for future treatment of anxiety disorders

Researchers at the University of Puerto Rico, School of Medicine have found a way to pharmacologically induce a memory of safety in the brain of rats. As reported in the June, 4 2010 issue of Science, administering brain-derived neurotrophic factor into the prefrontal cortex prevented rats from expressing fear to a tone that had been previously paired with a shock.

4 Jun 2010

Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

Hiru Corporation and its European subsidiary MindUp BioResearch comment on the recent research findings in the field of cancer treatments for multi-drug resistant non-small cell lung cancer.

4 Jun 2010

R-Tech Ueno announces completion of Phase II clinical study of UF-021 for retinitis pigmentosa

We are pleased to announce that the Phase II clinical study of UF-021, product name Ocuseva, which we are developing as a therapeutic drug for retinitis pigmentosa, has been completed.

4 Jun 2010

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

ViiV Healthcare to provide additional cost savings to cash-strapped ADAPs

AHF is pleased to report that yet another drug company: ViiV Healthcare, a new drug company formed in a partnership between GSK and Pfizer, has announced an agreement that will provide additional cost savings to cash-strapped ADAPs nationwide.

4 Jun 2010

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Royal Philips Electronics and RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference.

4 Jun 2010

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

Intellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent related to the Company's humanized monoclonal antibody, IN-N01, being developed as a disease-modifying treatment for Alzheimer's disease and other related indications.

4 Jun 2010

European countries focus on drug price cuts

"European governments grappling to reduce large budget deficits are focusing their cost-cutting on a large spending item — pharmaceuticals," The Wall Street Journal reports. "Several countries in recent weeks, including Spain, Germany and Italy, have proposed or enacted reductions in what they will pay or taken other cost-control measures for various drugs.

4 Jun 2010

Drugs News and Research

Strategy for harnessing physics for health

Caltech biologists pinpoint molecular changes that help allow global spread of resistance to Tamiflu

Functional profiling using EVA/PCD for prescribing treatment regimens for Stage IV NSCLC improve survival

Study: Rash adolescent behaviors tied to biological motivations

Physicians and researchers to present 16 abstracts on cancer research at ASCO 2010

Multiple sclerosis risk sharing scheme: A costly failure

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Chemotherapy-induced amenorrhea improves survival in premenopausal women with early stage breast cancer

Anti-seizure drug can be used to treat AT deficiency: Pitt researchers

20% of returning war veterans report PTSD or major depression

Key regulator of fat cell differentiation identified

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

Research finding suggests possibilities for future treatment of anxiety disorders

Hiru, MindUp BioResearch comment on recent research findings in cancer treatments

R-Tech Ueno announces completion of Phase II clinical study of UF-021 for retinitis pigmentosa

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

ViiV Healthcare to provide additional cost savings to cash-strapped ADAPs

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patent

European countries focus on drug price cuts

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News